Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

What impact could an approval of Opdivo in Hodgkin's Lymphoma data do to the current treatment options, specifically Adcetris?

Ticker(s): SGEN, BMY

Who's the expert?

Name: Dr Robert Soiffer - MD

Institution: Dana Farber Cancer Institute

Bio:

  • Chief of the Division of Hematologic Malignancies and co-director of the Adult Stem Cell Transplantation Program
  • Chairman of the Center for International Blood and Marrow Transplant Research advisory committee and has served as vice president (2006), president (2007), and immediate past president (2008) of the American Society of Blood and Marrow Transplantation.
  • Authored a number of articles in peer reviewed journal and member of several professional organizations

Interview Questions
Q1.

Please describe your background treating Hodgkin's Lymphoma patients. How many do you currently care for?

Added By: joe_mccann
Q2.

Please compare and contrast the experience you have treating patients with Adcetris and the what we know currently about Opdivo's experience in HL.

Added By: joe_mccann
Q3.

How does your real world experience with Adcetris compare to the label? Are there ways that doctors and patients are mitigating some of these side effects?

Added By: joe_mccann
Q4.

How would you compare the side effect profiles of Opdivo and Adcetris based on what we currently know?

Added By: joe_mccann
Q5.

If Opdivo is able to replicate the data published in the NEJM and presented at ASH (87% response rate for Treatment of Relapsed or Refractory Hodgkins Lymphoma) what role do you see for Adcetris going forward?  (assuming Opdivo is approved)

Added By: joe_mccann
Q6.

Given the age of empowerment by the internet of the public, how do you expect the HL market to fall after Opdivo is available....will 1st line and 2nd line and maintenance see a different split?

Added By: usercdb8aa0e
Q7.

How do elderly/frail handle the tox from Adcetris and how many are unable to get full cycles?

Added By: usercdb8aa0e

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.